β-Sitosterol laurate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: β-Sitosterol laurate
• 英文别名: lauric acid β-sitostenol ester；[(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] dodecanoate
• 化学式: C₄₁H₇₂O₂
• 分子量: 597.021
• InChiKey: ZKAAVBQKARRBFN-CIKJAVNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.1
• 重原子数：
  43
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  月桂酸甲酯 、 豆甾醇 在 sol-gel magnesium oxide supported on alumina 作用下， 反应 7.0h， 生成 β-Sitosterol laurate
  参考文献：
  名称：

  Selective synthesis of phytosterol esters from natural sterols and fatty methyl esters over Mg-containing solid catalysts

  摘要：

  植物甾醇酯可用于食品应用以及化妆品，同时表现出优于植物甾醇天然抗氧化剂的优势，具有更好的脂溶性和相容性。本文描述了一种基于脂肪甲酯与天然甾醇在没有任何溶剂的情况下使用碱性固体可重复使用催化剂进行酯交换反应的绿色化学工艺。事实证明，氧化铝负载的氧化镁具有特别高的选择性，与之前使用的其他碱性氧化物催化剂相比，其产率大大提高（93％），从而提供了所需的植物甾醇酯。由于适当的酸碱特性，当通过溶胶-凝胶途径制备用作 MgO 载体的氧化铝时，获得了最相关的结果。煅烧温度对催化行为有很大影响。研究还表明，固体催化剂的重复利用特性非常优异。 植物甾醇酯在食品工业和化妆品中的应用非常广泛，与天然植物甾醇、亲脂性物质和配方中的亲脂性物质融为一体。在该研究中，无溶剂的甲基酯和天然甾体酯的转酯化过程以及无溶剂的催化剂的存在是可回收的。铝氧化镁载体催化剂根据具体选择，可与所需的甾体酯一起反应（93%），与基本氧化剂进行比较realablement utilisés。这些结果表明，在溶胶-凝胶合成铝中，MgO 具有良好的支撑作用，并且具有适应酸反应的特性。煅烧温度对催化性能具有不可抗力影响。本研究展示了催化剂的卓越稳定性。

  DOI：

  10.1016/j.crci.2011.05.007

文献信息

• Lanthanum oxides for the selective synthesis of phytosterol esters: Correlation between catalytic and acid–base properties
  作者：S VALANGE、A BEAUCHAUD、J BARRAULT、Z GABELICA、M DATURI、F CAN

  DOI：10.1016/j.jcat.2007.07.004

  日期：2007.10.1

  The selective synthesis of phytosterol esters from natural sterols and methyl esters was investigated on new grounds by a chemical process using basic solids that are reusable, active, and more selective than the currently used homogeneous catalysts (e.g., alkali hydroxides, carbonates). Various lanthanum oxides with different synthesis procedures and varying specific surface areas were tested. The catalytic performance of the new solids and, more specifically, the ability of La2O3 oxides in increasing phytosterol ester selectivity, was correlated with their acido-basic properties, which were fully characterized by infrared spectroscopy. All La2O3 oxides involved surface carbonate species with different structural states and strengths, as revealed by propyne adsorption. The selectivity to phytosterol ester varied from 90 to 96%, confirming that the side reaction of dehydration of beta-sitosterol was strongly inhibited. The phytosterol ester yield could reach 89% and was related to the basic strength of the carbonate species. The lower the carbonate basicity, the higher the phytosterol ester yield. Moreover, IR spectra of catalysts diluted in KBr powder showed that the higher the intensity of unidentate carbonate bands, the higher the yield. It was concluded that the synthesis of phytosterol esters from fatty methyl esters and sitosterols in the presence of La2O3 catalysts requires ionic carbonate species of medium basic strength. (c) 2007 Elsevier Inc. All rights reserved.
• [EN] COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING CHOLESTEROL<br/>[FR] REVÊTEMENTS POUR DISPOSITIFS MÉDICAUX IMPLANTABLES COMPRENANT DU CHOLESTÉROL
  申请人：MIV THERAPEUTICS INC

  公开号：WO2008077247A1

  公开（公告）日：2008-07-03

  [EN] Disclosed herein are solid film coatings for implantable medical devices comprising a solid film covering at least a portion of the device. The solid film comprises: at least one lipid selected from cholesterol and cholesterol derivatives, at least one additional solid lipid other than cholesterol and cholesterol derivatives, and a therapeutically effective amount of at least one pharmaceutically active agent. Also disclosed herein are methods of preparing film coatings and methods of treating diseases with the implantable devices.
  [FR] La présente invention concerne des revêtements en pellicule solide pour dispositifs médicaux implantables comprenant une pellicule solide recouvrant au moins une partie du dispositif. La pellicule solide comprend : au moins un lipide choisi parmi le cholestérol et des dérivés du cholestérol; au moins un lipide solide supplémentaire autre que le cholestérol et les dérivés du cholestérol; et une quantité thérapeutiquement efficace d'au moins un agent pharmaceutiquement actif. Cette invention concerne également des procédés de préparation de revêtements pelliculaires et des méthodes de traitement de maladies utilisant ces dispositifs implantables.